Jianhong L. Li

Dr. Jianhong L. Li

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2015 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
LWLaixing Wang
Laixing Wang
JLJianwei Li
Jianwei Li
JHJian-Yue Huang
Jian-Yue Huang
JLJianhong L. Li
Jianhong L. Li
LZLi-Jun Zhang
Li-Jun Zhang
ZCZhi-Long Chen
Zhi-Long Chen

25 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
BLBingyu Li
Bingyu Li
LHLarry Huang
Larry Huang
JHJialing Huang
Jialing Huang
JLJianhong L. Li
Jianhong L. Li
Hepatocellular carcinoma (HCC) remains a global health challenge due to molecular heterogeneity and frequent delayed diagnosis. This comprehensive review synthesizes recent immunohistochemistry (IHC) advancements for HCC diagnosis, prognostication, and therapeutic prediction. We systematically evaluate conventional markers, such as hepatocyte paraffin 1 (HepPar1), arginase-1 (Arg-1), and glypican-3 (GPC3), as well as emerging biomarkers, detailing their diagnostic sensitivities and specificities in HCC with varied tumor differentiation. Prognostic immunostaining markers, such as Ki-67 proliferation index and vascular endothelial growth factor (VEGF) overexpression, correlate with reduced 5-year survival, while novel immune checkpoint IHC markers (PD-L1 and CTLA-4) predict response to immunotherapy, particularly in advanced HCC. This work provides evidence-based recommendations for optimizing IHC utilization in clinical practice while identifying knowledge gaps in biomarker validation and standardization.

19 April 2023 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JLJianhong L. Li
Jianhong L. Li
MWMyra L. Wilkerson
Myra L. Wilkerson
FDFang-Ming Deng
Fang-Ming Deng
HLHaiyan Liu
Haiyan Liu
Context.—: The morphologic features of different entities in genitourinary pathology overlap, presenting a diagnostic challenge, especially when diagnostic materials are limited. Immunohistochemical markers are valuable when morphologic features alone are insufficient for definitive diagnosis. The World Health Organization classification of urinary and male genital tumors has been updated for 2022. An updated review of immunohistochemical markers for newly classified genitourinary neoplasms and their differential diagnosis is needed. Objective.—: To review immunohistochemical markers used in the diagnosis of genitourinary lesions in the kidney, bladder, prostate, and testis. We particularly emphasized difficult differential diagnosis and pitfalls in immunohistochemistry application and interpretation. New markers and new entities in the 2022 World Health Organization classifications of genitourinary tumors are reviewed. Recommended staining panels for commonly encountered difficult differential diagnoses and potential pitfalls are discussed. Data Sources.—: Review of current literature and our own experience. Conclusions.—: Immunohistochemistry is a valuable tool in the diagnosis of problematic lesions of the genitourinary tract. However, the immunostains must be carefully interpreted in the context of morphologic findings with a thorough knowledge of pitfalls and limitations.

15 June 2022
Verified
Book Chapter
Closed access
PDF file
JLJianhong L. Li
Jianhong L. Li
ZCZongming Eric Chen
Zongming Eric Chen
FLFan Lin
Fan Lin

2 August 2026
Verified
Book Chapter
Closed access
PDF file
JLJianhong L. Li
Jianhong L. Li
MWMyra L. Wilkerson
Myra L. Wilkerson

1 October 2025
Verified
Book Chapter
Closed access
PDF file
JLJianhong L. Li
Jianhong L. Li
JLJinhong Li
Jinhong Li
ZCZongxian Cao
Zongxian Cao